These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3101105)

  • 21. Vasopressin antagonists block peripheral as well as central vasopressin receptors.
    De Wied D; Gaffori O; Van Ree JM; De Jong W
    Pharmacol Biochem Behav; 1984 Sep; 21(3):393-400. PubMed ID: 6093152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vasopressin fragment, AVP-(4-8), improves long-term and short-term memory in the hole board search task.
    Vawter MP; De Wied D; Van Ree JM
    Neuropeptides; 1997 Oct; 31(5):489-94. PubMed ID: 9413027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of AVP and DGAVP on the exploratory activity of rats.
    Skopková J; Lát J; Dvorská I; Hrbas P; Radil T
    Peptides; 1987; 8(5):785-90. PubMed ID: 3432126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interactive effects of neurohypophyseal neuropeptides with receptor antagonists on passive avoidance behavior: mediation by a cerebral neurohypophyseal hormone receptor?
    de Wied D; Elands J; Kovács G
    Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1494-8. PubMed ID: 1847526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hormonally active arginine-vasopressin suppresses endotoxin-induced fever in rats: lack of effect of oxytocin and a behaviorally active vasopressin fragment.
    Kovács GL; De Wied D
    Neuroendocrinology; 1983 Oct; 37(4):258-61. PubMed ID: 6355890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Further evidence for a dissociation of peripheral and central effects of vasopressin.
    Gaffori O; de Wied D
    Psychoneuroendocrinology; 1985; 10(4):439-44. PubMed ID: 4089084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can aversive properties of (peripherally-injected) vasopressin account for its putative role in memory?
    Ettenberg A; van der Kooy D; Le Moal M; Koob GF; Bloom FE
    Behav Brain Res; 1983 Mar; 7(3):331-50. PubMed ID: 6838716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The slowing of the extinction of a conditioned reaction and the antiamnesic action of arginine vasopressin and des-glycine-(8-arginine) vasopressin].
    Dubrovina NI; Papsuevich OS; Chipens GI
    Farmakol Toksikol; 1991; 54(5):5-7. PubMed ID: 1800150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of vasopressin analog [d(CH2)1(5),Tyr(Me)2]AVP on learning and memory in rats chronically treated with ethanol.
    Car H; Borawska MH; Wiśniewski K
    Pol J Pharmacol; 1993; 45(5-6):503-12. PubMed ID: 8012473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Passive avoidance learning in the rat as functions of d-amphetamine dosage and shock intensity.
    Seliger DL
    Psychopharmacology (Berl); 1977 Nov; 54(3):241-2. PubMed ID: 413139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of the synthetic analogue of vasopressin (DGAVP) at systemic and local application on the behaviour of the laboratory rat.
    Koupilová M; Herink J; Hrdina V; Barth T
    Act Nerv Super (Praha); 1989 Oct; 31(3):224-5. PubMed ID: 2588984
    [No Abstract]   [Full Text] [Related]  

  • 32. Neonatal administration of vasopressin antiserum induces long-term deficits on active and passive avoidance behaviour in rats.
    Moratalla R; Borrell J; Sanchez-Franco F; Del Rio J
    Behav Brain Res; 1987 Mar; 23(3):231-7. PubMed ID: 3580108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cysteinyl methyl ester of AVP(4-8), a potent agonist on the maintenance of passive avoidance in rats.
    Lin C; Liu RY; Du YC
    Peptides; 1990; 11(4):633-9. PubMed ID: 2235674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of vasopressin and analogue [d(CH2)1(5), Tyr (Me)2, Val4, delta 3Pro7)] AVP on learning and memory in rats chronically treated with ethanol.
    Car H; Borawska MH; Wiśniewski K
    J Physiol Pharmacol; 1994 Mar; 45(1):163-71. PubMed ID: 8043905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vasopressin neuropeptides and acquisition of heroin and cocaine self-administration in rats.
    van Ree JM; Burbach-Bloemarts EM; Wallace M
    Life Sci; 1988; 42(10):1091-9. PubMed ID: 3347140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Choice, as opposed to latency, measures in avoidance suggest that vasopressin and oxytocin do not affect memory in rats.
    Sahgal A; Wright C
    Neurosci Lett; 1984 Aug; 48(3):299-304. PubMed ID: 6483287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specificity of aversive stimulus properties of vasopressin.
    Bluthé RM; Dantzer R; Mormède P; Le Moal M
    Psychopharmacology (Berl); 1985; 87(2):238-41. PubMed ID: 3931152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vasopressin(1-8) (des-glycinamide9-[Arg8]vasopressin) is an endogenous peptide present in rat plasma.
    Laczi F; Burbach JP; Van der Kleij AA; De Wied D; Wiegant VM
    Peptides; 1991; 12(2):329-32. PubMed ID: 2067985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Greater task difficulty amplifies the facilitatory effect of des-glycinamide arginine vasopressin on appetitively motivated learning.
    Messing RB; Sparber SB
    Behav Neurosci; 1985 Dec; 99(6):1114-9. PubMed ID: 3843542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Facilitation of passive avoidance response by newly synthesized cationized arginine vasopressin fragment 4-9 in rats.
    Tanabe S; Shishido Y; Furushiro M; Kado K; Hashimoto S; Yokokura T; Ohsawa T
    Pharmacol Biochem Behav; 1997; 57(1-2):251-6. PubMed ID: 9164579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.